In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis

Lewiå„Ski A, Brona A, Lewandowski Kc, Skowroå„Ska-Jóåºwiak E, Milewicz, Milewicz A

Description

Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, and anti-inflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by radioiodine therapy (RIT). Material and methods We measured serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, and adiponectin, TSH, free T 4 (FT 4 ) and free T 3 (FT 3 ) in 15 patients (4 males), age (years) 51.8±15.3 (mean±SD) with hyperthyroidism treated with thiamazole (Group 1) and in 20 subjects (2 males), treated for thyrotoxicosis with radioiodine, age 52.3±12.4 (Group 2), where blood samples were taken before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2), and two to three months post RIT, visit 3 (V3). Results In Group 1 there was no significant change in concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 or adiponectin, despite a fall in FT 4 and FT 3 (8.74±4.79 pg/ml vs 3.54±2.40 pg/ml, for FT 3 , and 4.48 ±2.21 ng/ml vs 1.02±1.07 ng/ml, for FT 4 , p<0.001). In Group 2 RIT did not cause any acute change in serum MMP-2, MMP-9, TIMP-1 and TIMP-2 or adiponectin (V1 vs V2). However, there was a significant increase in serum adiponectin [from 15201±8860 ng/ml (V1) to 19373±8657 ng/ml (at V3), p<0.05], and TIMP-2 at V3 [from 129±45 ng/ml (V1) to 149±38 ng/ml (V3), p<0.01]. There was no significant change MMP-2, MMP-9 and TIMP-1 between V1 and V3. There was a decrease in FT 4 and FT 3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT 4 and FT 3 , respectively. Conclusions Radioiodine therapy of thyrotoxicosis does not alter serum MMP-2, MMP-9 or TIMP-1 concentrations either acutely or after about three months of observation. An increase in serum adiponectin might reflect favourable effects of radioiodine administration on cardiovascular risk factors, while an increase in TIMP-2 (principal MMP-2 inhibitor) might lead to a decrease in free MMP-2 concentrations.

Sujets

• Matrix metalloproteinase
• Adiponectin
• Hyperthyroidism
• Iodine-131

Informations

• Publié par: biomed
• Publié le: 01 janvier 2012
• Nombre de lectures: 5
• Langue: English

Extrait

Lewińskiet al. Thyroid Research2012,5:12 http://www.thyroidresearchjournal.com/content/5/1/12

R E S E A R C HOpen Access In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis 1* 21 12 A LewińA Brona , KC Lewandowski , E Skowroski ,ńskaJóźwiak andA Milewicz

Abstract Background:Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, and antiinflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by radioiodine therapy (RIT). Material and methods:We measured serum concentrations of MMP2, MMP9, TIMP1, TIMP2, and adiponectin, TSH, free T 4 (FT 4 ) and free T 3 (FT 3 ) in 15 patients (4 males), age (years) 51.8±15.3 (mean±SD) with hyperthyroidism treated with thiamazole (Group 1) and in 20 subjects (2 males), treated for thyrotoxicosis with radioiodine, age 52.3±12.4 (Group 2), where blood samples were taken before RIT, visit 1 (V1), seven days post RIT, visit 2 (V2), and two to three months post RIT, visit 3 (V3). Results:In Group 1 there was no significant change in concentrations of MMP2, MMP9, TIMP1, TIMP2 or adiponectin, despite a fall in FT 4 and FT 3 (8.74±4.79 pg/ml vs 3.54±2.40 pg/ml, for FT 3 , and 4.48 ±2.21 ng/ml vs 1.02±1.07 ng/ml, for FT 4 , p<0.001). In Group 2 RIT did not cause any acute change in serum MMP2, MMP9, TIMP1 and TIMP2 or adiponectin (V1 vs V2). However, there was a significant increase in serum adiponectin [from 15201 ±8860 ng/ml (V1) to 19373±8657 ng/ml (at V3), p<0.05], and TIMP2 at V3 [from 129±45 ng/ml (V1) to 149±38 ng/ ml (V3), p<0.01]. There was no significant change MMP2, MMP9 and TIMP1 between V1 and V3. There was a decrease in FT 4 and FT 3 from 24.4±15.4 pmol/l (V1) to 14.7±10.6 pmol/l (V3), and from 10.0±5.65 (V1) to 6.1±4.8 pmol/l (V2), p<0.01, for FT 4 and FT 3 , respectively. Conclusions:Radioiodine therapy of thyrotoxicosis does not alter serum MMP2, MMP9 or TIMP1 concentrations either acutely or after about three months of observation. An increase in serum adiponectin might reflect favourable effects of radioiodine administration on cardiovascular risk factors, while an increase in TIMP2 (principal MMP2 inhibitor) might lead to a decrease in free MMP2 concentrations. Keywords:Matrix metalloproteinases, Adiponectin, Thyrotoxicosis, Radioactive iodine

Introduction The term matrix metalloproteinases (MMPs) refers to a group of enzymes that remodel extracellular matrix in various physiological and pathological conditions, such as neoplasms, inflammatory and cardiovascular diseases [1]. In particular, increased activity of MMPs in blood

* Correspondence: [e-mail] 1 Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Rzgowska St. No. 281/289, 93338 Lodz, Poland Full list of author information is available at the end of the article

vessels has been implicated in formation of aneurysms [2], as well as in formation of unstable atherosclerotic plaques, in turn, leading to an increased risk of throm botic and embolic events, including myocardial infarc tions and strokes [35]. Adiponectin is an abundant plasma protein secreted from adipocytes. It has been thought to be a key mol ecule in the development of type 2 diabetes mellitus and metabolic syndrome, which are epidemiological targets for preventing cardiovascular disease. In addition to

© 2012 Lewiński et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.